All content material to ensure that it’s valuable to a a great deal wider population. The European principles of management of headache disorders in key care, laid out in 11 sections, will be the core from the content. Every single of these is more-or-less stand-alone, in an effort to act as practicalThe Journal of Headache and Discomfort 2017, 18(Suppl 1):Page 10 ofmanagement aids also as educational sources. There is a set of more practical management aids. An abbreviated version with the International Classification of Headache Disorders, 3rd edition (ICHD3), supplies diagnostic criteria for the few headache issues relevant to main care. A headache diary additional assists diagnosis as well as a headache calendar assists follow-up. A measure of headache impact (the HALT-90 index) may be employed in pre-treatment assessment of illness severity, and an outcome measure (the HURT questionnaire) is actually a guide to follow-up and require for treatment-review. 5 patient information and facts leaflets are included, which might be provided to individuals to enhance their understanding of their headache issues and their management. LTB and EHF supply these aids freely obtainable for use without restriction. We hope for benefits for each physicians and sufferers. S33 Combined hormonal contraception and migraine, WHO and EHF ESCRH criteria and balancing dangers and benefit Simona Sacco ([email protected]) Neurology section, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy The Journal of Headache and Pain 2017, 18(Suppl 1):S33 Quite a few data indicate that migraine, in particular migraine with aura, is linked with an increased danger of ischemic stroke and also other vascular events. Of concern is irrespective of whether the risk of ischemic stroke in migraineurs is magnified by the use of hormonal contraceptives (HCs). As migraine prevalence is high in girls of reproductive age, it really is popular to face the concern of migraine and HC use in clinical practice. To improve decision-making on the use of HCs in girls with migraine, a selected group of representatives from the European Headache Federation (EHF) plus the European Society of Contraception and Reproductive Health (ESC) developed a Consensus Statement on this topic. The document pointed out that evidence addressing the threat of ischemic stroke linked using the use of HCs is normally poor. All facts relies on observational data, which may well carry the risk of prospective bias. Available studies had different settings and used distinctive groups for comparing risks, limiting dependable comparison of research as a pooled analysis of information. A lot of the offered research were published a number of years ago and utilised compounds that are unique from those out there right now. Also, in most studies not sufficient information and facts is available with regards to the type of HC deemed and in most instances outcomes usually are not provided as outlined by migraine type. In spite of those limitations, out there data pointed toward an elevated danger of ischemic stroke associated with all the use of HCs in ladies with migraine. Literature indicated that, whereas combined HCs carry a specific danger of arterial ischemic events this doesn’t happen for progestogens-only HCs that are deemed safe when it comes to Fluticasone furoate site cardiovascular threat even within the presence of related risk things. Thinking about these data, and unless studies will prove safety in the use of combined HCs in women with migraine, the recommendations in the Consensus Group gave priority to safety and suggested a number of limit.